DCM
MRNS

DAFNA Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

DAFNA Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-22,559
Closed -$115K – 96
2016
Q2 		$115K Sell
22,559
-119,066
-84% -$2.19M 0.09% 84
2016
Q1 		$3.05M Hold
141,625
– – 2.63% 9
2015
Q4 		$4.33M Buy
141,625
+136,045
+2,438% +$3.99M 3.86% 4
2015
Q3 		$186K Hold
5,580
– – 0.18% 73
2015
Q2 		$259K Buy
+5,580
New +$208K 0.22% 61

Other funds holding MRNS

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

DAFNA Capital Management's MRNS Position: Q3 2016 in Review

DAFNA Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2016, closing a stake of 22,559 shares — an estimated $115K sold.

DAFNA Capital Management first reported a position in MRNS in Q2 2015 and held it in 5 quarters. The position peaked at $4.33M in Q4 2015. 26 funds tracked by Wall St. Rank hold MRNS as of Q3 2016.

  • DAFNA Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 22,559 Marinus Pharmaceuticals, Inc shares in Q3 2016, an estimated $115K.
  • DAFNA Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 5 quarters.
  • DAFNA Capital Management's Marinus Pharmaceuticals, Inc position peaked at $4.33M in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.